TW445259B - Use of derivatives of aryl (or heteroaryl) azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance P - Google Patents

Use of derivatives of aryl (or heteroaryl) azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance P Download PDF

Info

Publication number
TW445259B
TW445259B TW088113353A TW88113353A TW445259B TW 445259 B TW445259 B TW 445259B TW 088113353 A TW088113353 A TW 088113353A TW 88113353 A TW88113353 A TW 88113353A TW 445259 B TW445259 B TW 445259B
Authority
TW
Taiwan
Prior art keywords
radical
ministry
group
economic affairs
quot
Prior art date
Application number
TW088113353A
Other languages
English (en)
Chinese (zh)
Inventor
Ramon Merce-Vidal
Jordi Frigola-Constansa
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Application granted granted Critical
Publication of TW445259B publication Critical patent/TW445259B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW088113353A 1998-08-07 1999-08-05 Use of derivatives of aryl (or heteroaryl) azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance P TW445259B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.

Publications (1)

Publication Number Publication Date
TW445259B true TW445259B (en) 2001-07-11

Family

ID=8304839

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088113353A TW445259B (en) 1998-08-07 1999-08-05 Use of derivatives of aryl (or heteroaryl) azolylcarbinols in the manufacture of a medicament for the treatment of disorders mediated by an excess of substance P

Country Status (26)

Country Link
US (1) US6518295B1 (cg-RX-API-DMAC7.html)
EP (1) EP1103243B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002522359A (cg-RX-API-DMAC7.html)
KR (1) KR100558506B1 (cg-RX-API-DMAC7.html)
CN (1) CN1151789C (cg-RX-API-DMAC7.html)
AR (1) AR019999A1 (cg-RX-API-DMAC7.html)
AT (1) ATE257379T1 (cg-RX-API-DMAC7.html)
AU (1) AU754124B2 (cg-RX-API-DMAC7.html)
BR (1) BR9912807A (cg-RX-API-DMAC7.html)
CA (1) CA2339661C (cg-RX-API-DMAC7.html)
CO (1) CO5080747A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ292065B6 (cg-RX-API-DMAC7.html)
DE (1) DE69914085T8 (cg-RX-API-DMAC7.html)
DK (1) DK1103243T3 (cg-RX-API-DMAC7.html)
ES (2) ES2150378B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0105428A3 (cg-RX-API-DMAC7.html)
IL (1) IL141295A0 (cg-RX-API-DMAC7.html)
NO (1) NO20010634L (cg-RX-API-DMAC7.html)
NZ (1) NZ509645A (cg-RX-API-DMAC7.html)
PL (1) PL193802B1 (cg-RX-API-DMAC7.html)
PT (1) PT1103243E (cg-RX-API-DMAC7.html)
RU (1) RU2223116C2 (cg-RX-API-DMAC7.html)
TR (1) TR200100378T2 (cg-RX-API-DMAC7.html)
TW (1) TW445259B (cg-RX-API-DMAC7.html)
WO (1) WO2000007542A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200100867B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174756B2 (es) * 2001-04-06 2003-11-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
DE10335566A1 (de) * 2003-07-31 2005-02-24 Grünenthal GmbH Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
WO2006010627A1 (en) * 2004-07-30 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Aryl (or heteroaryl) azolylcarbinols
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
ES2286920B1 (es) * 2005-02-15 2008-08-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
WO2006087147A2 (en) * 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1695704A1 (en) * 2005-02-28 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1690537A1 (en) * 2005-02-15 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia
CA2637312A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
MX2009003801A (es) 2006-10-19 2009-04-22 Hoffmann La Roche Aminometil-4-imidazoles.
BRPI0718054A2 (pt) 2006-11-02 2013-11-05 Hoffmann La Roche 2-imidazóis substituídos como moduladores de receptores associados à traços de aminas
AU2007321376A1 (en) 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
WO2008071574A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2 -imidazoles as ligands for trace amine associated receptors (taar)
CA2675221C (en) 2007-02-02 2016-02-23 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as taar1 ligands
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
CA2691082A1 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
BRPI0812833A2 (pt) 2007-07-03 2014-12-09 Hoffmann La Roche 4-imidazolinas e seu uso como antidepressivos
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Taar 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
CA2695331A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
WO2010123999A2 (en) * 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
RS60825B1 (sr) 2016-03-17 2020-10-30 Hoffmann La Roche Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613720B1 (fr) * 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
FR2681322B1 (fr) * 1991-09-12 1993-12-17 Laboratorios Dr Esteve Sa Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments .
CA2154116A1 (en) * 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
FR2742147B1 (fr) * 1995-12-06 1998-02-27 Esteve Labor Dr Procede de separation de carbinols
ES2234039T3 (es) * 1996-12-02 2005-06-16 MERCK SHARP & DOHME LTD. Uso de antagonistas del receptor nk-1 para tratar trastornos de depresion mayor.
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders
EP0942735A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating schizophrenic disorders
WO1998024447A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
AU5422999A (en) 2000-02-28
HUP0105428A3 (en) 2003-01-28
CZ292065B6 (cs) 2003-07-16
CO5080747A1 (es) 2001-09-25
ES2150378B1 (es) 2001-07-01
NZ509645A (en) 2003-01-31
IL141295A0 (en) 2002-12-01
WO2000007542A2 (es) 2000-02-17
TR200100378T2 (tr) 2001-06-21
DE69914085T2 (de) 2004-11-25
ES2213380T3 (es) 2004-08-16
ES2150378A1 (es) 2000-11-16
DE69914085T8 (de) 2005-04-21
ATE257379T1 (de) 2004-01-15
BR9912807A (pt) 2001-10-16
NO20010634D0 (no) 2001-02-06
RU2223116C2 (ru) 2004-02-10
AU754124B2 (en) 2002-11-07
PL193802B1 (pl) 2007-03-30
EP1103243B1 (en) 2004-01-07
CN1151789C (zh) 2004-06-02
KR20010079616A (ko) 2001-08-22
PL346221A1 (en) 2002-01-28
US6518295B1 (en) 2003-02-11
PT1103243E (pt) 2004-05-31
EP1103243A2 (en) 2001-05-30
WO2000007542A3 (es) 2000-05-11
CZ2001412A3 (cs) 2001-08-15
DE69914085D1 (de) 2004-02-12
ZA200100867B (en) 2001-08-16
CA2339661C (en) 2006-10-17
NO20010634L (no) 2001-04-06
CN1317966A (zh) 2001-10-17
JP2002522359A (ja) 2002-07-23
DK1103243T3 (da) 2004-05-03
CA2339661A1 (en) 2000-02-17
AR019999A1 (es) 2002-03-27
KR100558506B1 (ko) 2006-03-07
HUP0105428A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
TWI776407B (zh) 激動劑形成之調配物及使用其之方法
CN105168219B (zh) 用于睡眠障碍和其他疾病的方法和组合物
CN100415217C (zh) 腺苷A2a受体拮抗剂的应用
JP6245983B2 (ja) パーキンソン病におけるジスキネジアを治療するための新規d3ドーパミン受容体アゴニスト
US20100048713A1 (en) Compounds acting on the serotonin transporter
US6518295B1 (en) Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P
JP2006504795A (ja) 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
AU2025267332A1 (en) Psychotropic agents and uses thereof
BRPI0712976A2 (pt) uso de 2-aminotetralinas substituÍdas para a fabricaÇço de um medicamento para a prevenÇço, alÍvio e/ou tratamento de vÁrios tipos de dor
TWI226829B (en) Pharmaceutical compositions for treatment of partial responders or refractory depression
JP2012255039A (ja) ニコチン性アセチルコリンα7受容体アゴニストの組合せ剤
JP2011523949A5 (cg-RX-API-DMAC7.html)
CA2163840A1 (en) Potentiation of drug response
WO2006119958A2 (en) Use of flibanserin in the treatment of chronic pain
AU2018202410B2 (en) Methods for treating antipsychotic-induced weight gain
EP1988898A2 (en) Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
CA2530381C (fr) Association d'un antagoniste ou agoniste inverse du recepteur h3 de l'histamine avec un anti-psychotique ou un antidepresseur et son utilisation pour preparer un medicament prevenant des effets indesirables de medicaments psychotropes
KR20190049732A (ko) 5-ht2c 수용체 효능제 및 조성물 및 사용 방법
JP2013536859A (ja) 5−ht2cアゴニストの非吸湿性塩
DK2694065T3 (en) COMPOSITION FOR TREATMENT OF DISORDER WITH SEXUAL SEXUAL LISTENING
CN101163477A (zh) 多介质多巴胺转运抑制剂,以及其相关应用
SK287152B6 (sk) Použitie dezoxypeganínu na liečenie klinickej depresie
CA3049319A1 (en) Therapeutic agent for non-motor symptoms associated with parkinson's disease
MX2007002460A (es) Metodos para tratar trastornos del humor utilizando derivados azabiciclicos de piridiloximetilo y benzisoxazol.
WO2025245066A1 (en) Compositions and methods for affecting weight loss, weight management, sexual disorders, well-being, self-esteem, and/or self-confidence

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees